Find in Library

Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine, and entheses, which is associated with psoriasis. The pathological process is localized mainly in the tissues of the  locomotor system and leads to the development of erosive arthritis  and intra-articular osteolysis. PsA occurs in 5–7% of patients with  moderate psoriasis. Despite advances in the treatment of psoriasis  and PsA with diseasemodifying antirheumatic drugs (DMARDs) and  biological agents (BAs), the problems associated with  immunogenicity, infectious complications, and secondary inefficiency  have not been fully solved. These factors have motivated the search  for novel targeted synthetic drugs (signaling pathway inhibitors).  This group of drugs includes apremilast, a phosphodiesterase 4  inhibitor. Recent data of controlled studies suggest that the drug is effective and safe in treating psoriasis and PsA. Prospects for the use of apremilast in PsA are associated with the possibility to use the drug in patients because of the inefficacy of DMARDs or BAs and  with the ability to maintain long-term (more than 3-year) remission  and to reduce the manifestations of enthesitis and dactylitis.